about
Defining the clinical course of multiple sclerosis: the 2013 revisions.Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineUse of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum DisorderDisease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responsesRituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneityQuinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II moleculesPharmacological prion protein silencing accelerates central nervous system autoimmune disease via T cell receptor signallingAcute disseminated encephalomyelitis: an update.CNS intravascular lymphoma: a case reportPEG minocycline-liposomes ameliorate CNS autoimmune disease.Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.Acute disseminated encephalomyelitis: an acute hit against the brain.Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease.Statins as potential therapeutic agents in neuroinflammatory disorders.Isoniazid in autoimmunity: a trigger for multiple sclerosis?Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.Prion protein gene codon 129 modulates clinical course of neurological Wilson disease.The genetics of natalizumab hypersensitivity: One learns to itch where one can scratch.CD19 as a molecular target in CNS autoimmunity.Multiple sclerosis and chronic cerebrospinal venous insufficiency: a critical reviewIdiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choicesApproved and future pharmacotherapy for multiple sclerosis.Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.Statins and their potential targets in multiple sclerosis therapy.Statins as potential therapeutic agents in multiple sclerosis.Are statins a treatment option for multiple sclerosis?Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.From injection therapies to natalizumab: views on the treatment of multiple sclerosis.Statins--a cure-all for the brain?Putative mechanisms of action of statins in multiple sclerosis--comparison to interferon-beta and glatiramer acetate.Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation.Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.Therapeutic potential of small interfering RNA for central nervous system diseases.Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.Central nervous system infections - a potential complication of systemic immunotherapy.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis
P50
Q22241654-A08B5D83-DC85-43E3-8EB7-4603BB8A6760Q24597369-3224DDB0-5480-4C66-904D-BC433787541DQ28085378-DF2EF24C-2A5E-4310-A2C6-BA4EC26D22C8Q28289228-59D72C90-FE4F-478D-801D-7BF559960A6EQ28290005-F1C2BD55-AC59-4418-9AB1-AE03ED1B2207Q28478607-30DCF603-9DFC-4BE7-B753-37B061C6DFDFQ28506096-E6942130-5317-4453-9898-25ACE202C223Q31018411-DCE91481-DD7D-4C26-9D6C-678C3C830625Q33161705-FAF6AD22-3146-441E-A2CB-4F69413FDBABQ33398048-178434B7-B10A-428B-9672-AB28EE259523Q33832088-1F39F02C-9A38-4034-8C12-34DDB5F597CCQ34004095-EC819F50-610B-40B4-B383-82746E41A4B1Q34061505-F8360738-27B0-4873-9097-FE0ED3C71F28Q34080692-E2C16F19-41BF-423E-ABBA-B11DE8800A12Q34213875-4A08372A-6780-4F4B-AAB2-71A1396745E9Q34389312-8B8A9133-C7E9-436D-9282-2E5F7A081920Q34409273-481FC0BE-4131-4D42-BA47-8161610D3E75Q34409297-C0F3E7CA-ABDC-4933-9349-FA1A162D9724Q34448370-08873046-1297-4E9D-98E1-F0F50370ED8CQ34502965-3A11069C-98EF-4A24-B77A-AD8206CEF905Q34714513-3D4B1882-0B07-4FF9-9E58-6629C402C861Q34976749-918C8356-9DD8-4656-8526-252208C02FD1Q35090432-F792757F-0E18-41A4-984C-BDBECBBD3788Q35151856-508DC974-344D-4F5F-8A67-AF7C7297532EQ35153065-FA68FB19-2049-4EF9-AD63-259CA68E0675Q35212994-B69D9A83-CE75-4220-85A7-609CC2E9686EQ35537898-D96FDC4A-2749-4956-A256-11846869A457Q35753051-395BAD50-AF2D-4EE6-A6A2-68EF20CE2F90Q35781154-8DF62A81-D123-4690-A8D6-461F48A17B04Q35818165-93763308-0630-4B42-A2F6-1F0BD502C023Q35825914-7EF8C9B9-E769-4D26-9EED-831CC0707F44Q36085649-60F8F88E-DC57-4F3C-A1E0-66D8344F09C2Q36159251-F4190A80-F73A-4790-8CF8-ADC2636DDD41Q36166577-3566BAA5-DA2E-4C17-9575-3578CA23F304Q36174156-98AB8F77-C33D-4ABC-AB5A-F6B045DF2638Q36282742-BCE23B23-DEEB-4C5C-A4CE-A59DF379A129Q36339478-E721AC76-A754-4AE2-8F3F-CA8FB3FB363EQ36397463-E26131E3-5054-41D9-ADE7-6CB1A86333C9Q36479937-B36DD59C-FFF1-4941-8782-DACD721338C8Q36484443-9598A852-4963-46F6-AA92-2C2BD3E9C497
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Olaf Stüve
@ast
Olaf Stüve
@en
Olaf Stüve
@es
Olaf Stüve
@nl
Olaf Stüve
@sl
type
label
Olaf Stüve
@ast
Olaf Stüve
@en
Olaf Stüve
@es
Olaf Stüve
@nl
Olaf Stüve
@sl
prefLabel
Olaf Stüve
@ast
Olaf Stüve
@en
Olaf Stüve
@es
Olaf Stüve
@nl
Olaf Stüve
@sl